Format

Send to

Choose Destination
J Cancer. 2014 Aug 1;5(8):625-7. doi: 10.7150/jca.9730. eCollection 2014.

DAXAS and COPD Correlation with Cancer.

Author information

1
1. Pulmonary Department-Oncology Unit, ``G. Papanikolaou`` General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
2
2. Department of Respiratory Diseases Shanghai Hospital, II Military University Hospital, Shanghai, China.
3
3. Oncology Department, ``Sotiria`` Hospital of Chest Diseases, University of Athens, Athens, Greece.
4
4. Internal Medicine Department, ``Thegeneio`` Cancer Hospital, Thessaloniki, Greece.
5
5. II Medical Department, ``Coburg`` Regional Clinic, University of Wuerzburg, Coburg, Germany.
6
6. Department of Clinical Therapeutics, Division of Pneumonology, Medical School, National University of Athens, Athens, Greece.
7
7. Ruhrlandklinik, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany ; 8. Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
8
9. Internal Medicine Department, ``Theagenio`` Anti-Cancer Hospital, Thessaloniki, Greece.

Abstract

A new drug for chronic obstructive pulmonary disease has been recently added as a treatment for certain patients. However, new evidences indicate that there might be a connection with lung cancer. It is known that smoking is a major factor that induces chronic pulmonary disease and smoking is associated with lung cancer. The level of connection between phosphodiesterase (PDE)-4 inhibitors and lung cancer will be discussed based on current studies. A comment will be made whether lung cancer is induced to patients receiving phosphodiesterase (PDE)-4 inhibitors from the drug or former smoking habit.

KEYWORDS:

COPD; cancer.; inflammation; phosphodiesterase

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center